Clinical trials: Acute Heart Failure With Reduced Ejection Fraction
Acute Heart Failure
An Observational Study of the Functional Capacity of Heart Failure
This is an observational study of the functional capacity of patients with Heart failure with Reduced Ejection Fraction (HFrEF) who are admitted to the hospital for routine medical treatment.
- Trial name
- NCT02350114
- Testing
- 6 Minute Walk Test
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Heart Failure
Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF
Atrial fibrillation (AF) is the most common arrhythmia, accounting for one third of all hospital admissions and 1% of all emergency department visits (ED). Approximately 65% of those presenting to the ED with AF are admitted.
- Trial name
- NCT02938260
- Testing
- Metoprolol vs Diltiazem
- Volunteers
- 48 people
- Sponsor
- RaeAnn Hirschy
Heart Failure, Acute Myocardial Infarction
Carvedilol Vascular Efficacy Trial
Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction.
- Trial name
- CARVEDIA (NCT01484327)
- Testing
- Carvedilol
- Where
- Greece
- Volunteers
- 415 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy…
- Conditions
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BRIDGE (NCT07741396)
- Testing
- CBCR, BRIDGE mHealth intervention
- Volunteers
- 30 people
- Sponsor
- University of Illinois at Chicago
Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia
- Trial name
- LIFT (NCT05004363)
- Testing
- Lokelma Oral Product
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- St George's, University of London
Heart Failure With Reduced Ejection Fraction, Acute Heart Failure
Optimize Heart Failure Care During TRANSitional Period in Patients With Acute Heart Failure.
The period of about a month after the discharge of acute heart failure patients is defined as a transition time. During this period, the patient has a high mortality rate and a readmission rate because the patient is not…
- Trial name
- TRANS-HF (NCT04900584)
- Testing
- Checklist, Education, Telephone monitoring
- Where
- South Korea
- Volunteers
- 1,009 people
- Sponsor
- Wonju Severance Christian Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Acute heart failure (AHF) is defined as rapid onset or rapid worsening of typical signs and symptoms of heart failure (HF) according to the 2016 European Society of Cardiology Guidelines.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- FUTURE-HIT (NCT05204238)
- Testing
- Transthoracic Echocardiography
- Where
- 31 sites in Australia, Belgium and 10 more
- Volunteers
- 998 people
- Sponsor
- University of Siena
Acute Heart Failure
Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation
The AHF-CODE reduced study is a prospective, non-randomized, monocenter study performed in patients with heart failure with reduced ejection fraction admitted for worsening heart failure.
- Trial name
- AHF-CODE-R (NCT04343443)
- Testing
- Clinical examination centered on congestion, Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography, Biological: Blood sample retrieved for biological assessment and biobanking
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure, Acute Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Trial name
- REDEFINE-HF (NCT06008197)
- Testing
- Finerenone
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 5,200 people
- Sponsor
- Colorado Prevention Center
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent
Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment
With the aging of society, the use of cardiac pacing in patients with irreversible bradycardia is increasingly widespread. As early as the 1950s, right ventricular pacing (RVP) began to be used in patients with atrioventricular…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent, Sick Sinus Syndrome, Atrioventricular Block
- Trial name
- NCT05575557
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai 10th People's Hospital
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Acute Heart Failure (AHF), Acute Heart Failure With Reduced Ejection Fraction
Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction
VN-RAPID is an open-label, multicenter, randomized controlled trial evaluating the safety and efficacy of in-hospital initiation and rapid up-titration of four-pillar therapy for hospitalized Asian patients with acute heart…
- Trial name
- VN-RAPID (NCT06595290)
- Testing
- High intensity care, Usual care
- Where
- 4 sites in Vietnam
- Volunteers
- 500 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Acute Heart Failure, Chronic Kidney Diseases
Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
To investigate the effectiveness and feasibility of natriuresis-guided diuretic therapy as a personalized approach to managing acute heart failure in patients with underlying chronic kidney disease and its effect on short term…
- Trial name
- NCT06203236
- Testing
- Furosemide 20 MG, diuretic therapy
- Volunteers
- 300 people
- Sponsor
- Assiut University
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive
The FOCUS-ADHF Registry
Acute heart failure (AHF) represents a significant clinical and economic burden due to its impact on patients' quality of life, poor prognosis, and high healthcare costs.
- Conditions
- Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive, Regurgitation, Mitral
- Trial name
- FOCUS-ADHF (NCT06726109)
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 600 people
- Sponsor
- ASL Città di Torino
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)
Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
The proposed study is a sub-study of the CANTOS trial (A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable…
- Conditions
- Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
- Trial name
- NCT01900600
- Testing
- Cardiopulmonary exercise test, Echocardiogram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Virginia Commonwealth University
Heart Failure Acute, Diabetes Type 2
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for…
- Conditions
- Heart Failure Acute, Diabetes Type 2, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- DAPA-TONIC (NCT06442280)
- Testing
- Dapagliflozin tablet, Hypertonic Saline Solution, 1 Ml, Furosemide Injection
- Volunteers
- 544 people
- Sponsor
- University of Palermo
Heart Failure With Reduced Ejection Fraction (HFrEF), Hospitalization
Intravenous Iron Sucrose for Acute Decompensated Heart Failure Patients With Reduced Ejection Fraction and Iron Deficiency
Iron deficiency (ID) affects about 25% of the global population, presenting with symptoms of fatigue, weakness, and impaired cognitive function.
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Hospitalization, Iron Deficiency
- Trial name
- IronSucroseHF (NCT06703411)
- Testing
- Iron Sucrose IV, Standard Medical Therapy
- Where
- Taiwan
- Volunteers
- 76 people
- Sponsor
- Cheng-Hsin General Hospital
Acute Coronary Syndrome, Heart Failure With Reduced Ejection Fraction
Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection <45% between participants who take vericiguat regularly and those who donot.
- Trial name
- NCT06321094
- Where
- China
- Volunteers
- 149 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University